explore -WSS

explore

author：explore 2025-09-28 02:48:06 - browse：116

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Sutter Health’s antitrust win overturned by appeals court

WSS

Private equity deals in Medicare Advantage declines

PhRMA lawsuit over Medicare drug price negotiation tossed

A new initiative will help leaders fight the next pandemic

Elevance PBM president out as customers face prescription chaos

Data don't support strong claims for Covid

Senators tussle over abortion against the backdrop of a presidential campaign

entertainment

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

STAT wants to know your pick for a great summer read or listen

Peter Hotez and the public health issue of online harassment

'Little Tech' descents on D.C., wanting a say in how AI is regulated

What does generative AI mean for health care? We asked experts

Biogen Alzheimer’s drug launch off to slow start

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How digital tools helped lower hypertension in marginalized patients

Affirmative action in medical school literally saved lives

Eli Lilly’s Zepbound improved liver scarring in mid

Wikipedia

A disappointing year of Humira biosimilars

To avoid data mishandling cases, universities eye AI and other tools

Data don't support strong claims for Covid

Industry veterans launch new biotech VC with $310M

Senators start work on Medicare physician payment reform

Why did Pfizer dish out millions for a Super Bowl ad?

entertainment

explore

focus

entertainment